Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price Target & Predictions
AMPH Stock Forecast
Amphastar Pharmaceuticals stock forecast is as follows: an average price target of $66.00 (represents a 37.24% upside from AMPH’s last price of $48.09) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
AMPH Price Target
The average price target for Amphastar Pharmaceuticals (AMPH) is $66.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $66.00 to $66.00. This represents a potential 37.24% upside from AMPH's last price of $48.09.
AMPH Analyst Ratings
According to 1 Wall Street analysts, Amphastar Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AMPH stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Amphastar Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | David Amsellem | Piper Sandler | $66.00 | $43.30 | 52.41% | 37.24% |
| May 23, 2024 | David Amsellem | Piper Sandler | $71.00 | $43.31 | 63.93% | 47.64% |
| Mar 12, 2022 | David Amsellem | Piper Sandler | $35.00 | $34.30 | 2.04% | -27.22% |
The latest Amphastar Pharmaceuticals stock forecast, released on Aug 08, 2024 by David Amsellem from Piper Sandler, set a price target of $66.00, which represents a 52.41% increase from the stock price at the time of the forecast ($43.30), and a 37.24% increase from AMPH last price ($48.09).
Amphastar Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $66.00 | $68.50 |
| Last Closing Price | $48.09 | $48.09 | $48.09 |
| Upside/Downside | -100.00% | 37.24% | 42.44% |
In the current month, the average price target of Amphastar Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amphastar Pharmaceuticals's last price of $48.09. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 12, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Amphastar Pharmaceuticals's last stock rating was published by Piper Sandler on Aug 08, 2024. The company gave AMPH a "Overweight" rating, the same as its previous rate.
Amphastar Pharmaceuticals Financial Forecast
Amphastar Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $155.65M | - | $145.71M | $140.02M | $135.02M | $120.13M | $123.47M | $120.37M | $120.89M | $112.20M | $101.66M | $103.02M | $95.92M | $83.43M | $85.81M | $84.69M | $83.38M | $80.14M | $79.05M | $79.79M | $58.39M | $56.67M |
| Avg Forecast | $219.76M | $216.01M | $198.58M | $189.95M | $196.84M | $194.79M | $170.96M | $174.65M | $173.43M | $174.63M | $137.27M | $137.27M | $127.18M | $125.98M | $118.08M | $113.33M | $111.62M | $103.25M | $101.30M | $96.87M | $88.94M | $91.23M | $86.73M | $82.90M | $81.81M | $78.57M | $77.56M | $76.22M | $93.42M | $44.08M |
| High Forecast | $233.54M | $229.55M | $211.03M | $201.86M | $209.18M | $205.86M | $181.68M | $185.60M | $182.05M | $185.57M | $145.87M | $145.87M | $135.16M | $133.87M | $125.13M | $120.10M | $118.29M | $109.42M | $107.35M | $102.65M | $94.25M | $96.68M | $91.91M | $87.85M | $86.69M | $83.26M | $82.20M | $80.77M | $112.11M | $52.89M |
| Low Forecast | $212.22M | $208.59M | $191.76M | $183.43M | $190.08M | $187.19M | $165.09M | $168.65M | $164.80M | $168.63M | $132.55M | $132.55M | $122.82M | $121.65M | $113.75M | $109.17M | $107.52M | $99.46M | $97.59M | $93.31M | $85.68M | $87.89M | $83.55M | $79.86M | $78.80M | $75.68M | $74.72M | $73.42M | $74.74M | $35.26M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | 0.90% | - | 1.06% | 1.02% | 1.06% | 0.95% | 1.05% | 1.06% | 1.08% | 1.09% | 1.00% | 1.06% | 1.08% | 0.91% | 0.99% | 1.02% | 1.02% | 1.02% | 1.02% | 1.05% | 0.63% | 1.29% |
Amphastar Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $174.65M, with a low forecast of $168.65M, and a high forecast of $185.60M. AMPH's average Quarter revenue forecast represents a 12.21% increase compared to the company's last Quarter revenue of $155.65M (Dec 23).
Amphastar Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $53.98M | - | $36.90M | $33.43M | $37.83M | $23.23M | $24.82M | $36.18M | $33.67M | $43.27M | $20.31M | $13.13M | $-365.00K | $13.05M | $5.69M | $12.13M | $5.08M | $7.20M | $67.69M | $3.94M | $-5.08M | $5.52M |
| Avg Forecast | $34.33M | $33.74M | $31.02M | $29.67M | $30.75M | $30.43M | $26.70M | $27.28M | $27.09M | $27.28M | $21.44M | $21.44M | $19.87M | $30.84M | $18.44M | $24.64M | $17.43M | $16.13M | $15.82M | $7.22M | $13.89M | $14.25M | $13.55M | $11.19M | $12.78M | $12.27M | $12.12M | $2.17M | $-12.01M | $3.94M |
| High Forecast | $36.48M | $35.85M | $32.96M | $31.53M | $32.67M | $32.15M | $28.38M | $28.99M | $28.44M | $28.99M | $22.78M | $22.78M | $21.11M | $37.01M | $19.55M | $29.57M | $18.48M | $17.09M | $16.77M | $8.66M | $14.72M | $15.10M | $14.36M | $13.43M | $13.54M | $13.00M | $12.84M | $2.60M | $-9.60M | $4.73M |
| Low Forecast | $33.15M | $32.58M | $29.95M | $28.65M | $29.69M | $29.24M | $25.79M | $26.34M | $25.74M | $26.34M | $20.70M | $20.70M | $19.18M | $24.67M | $17.77M | $19.71M | $16.79M | $15.54M | $15.24M | $5.78M | $13.38M | $13.73M | $13.05M | $8.95M | $12.31M | $11.82M | $11.67M | $1.73M | $-14.41M | $3.15M |
| Surprise % | - | - | - | - | - | - | - | - | 1.99% | - | 1.72% | 1.56% | 1.90% | 0.75% | 1.35% | 1.47% | 1.93% | 2.68% | 1.28% | 1.82% | -0.03% | 0.92% | 0.42% | 1.08% | 0.40% | 0.59% | 5.59% | 1.82% | 0.42% | 1.40% |
1 analysts predict AMPH's average Quarter EBITDA for Mar 24 to be $27.28M, with a high of $28.99M and a low of $26.34M. This is -49.46% lower than Amphastar Pharmaceuticals's previous annual EBITDA (Dec 23) of $53.98M.
Amphastar Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $36.17M | - | $26.12M | $26.03M | $33.91M | $15.87M | $17.35M | $24.25M | $19.97M | $29.55M | $7.77M | $5.04M | $-6.27M | $3.92M | $-192.00K | $3.95M | $-1.03M | $1.31M | $47.79M | $868.00K | $-7.25M | $893.00K |
| Avg Forecast | $65.98M | $62.46M | $55.55M | $52.35M | $51.35M | $52.48M | $40.20M | $40.25M | $47.34M | $36.17M | $29.14M | $27.67M | $20.82M | $21.06M | $18.11M | $16.84M | $19.26M | $12.49M | $10.93M | $2.77M | $7.14M | $7.29M | $7.06M | $3.64M | $3.90M | $3.47M | $1.82M | $477.40K | $-17.12M | $637.86K |
| High Forecast | $71.36M | $67.55M | $60.07M | $56.62M | $55.54M | $58.08M | $43.47M | $43.53M | $52.78M | $39.12M | $31.51M | $29.93M | $22.52M | $25.27M | $19.52M | $20.21M | $20.75M | $13.46M | $11.78M | $3.33M | $7.69M | $7.85M | $7.61M | $4.37M | $4.21M | $3.74M | $1.96M | $572.88K | $-13.69M | $765.43K |
| Low Forecast | $63.04M | $59.68M | $53.07M | $50.01M | $49.06M | $46.37M | $38.40M | $38.45M | $40.81M | $34.56M | $27.84M | $26.44M | $19.89M | $16.85M | $17.25M | $13.47M | $18.34M | $11.90M | $10.41M | $2.22M | $6.80M | $6.94M | $6.73M | $2.91M | $3.72M | $3.30M | $1.73M | $381.92K | $-20.54M | $510.29K |
| Surprise % | - | - | - | - | - | - | - | - | 0.76% | - | 0.90% | 0.94% | 1.63% | 0.75% | 0.96% | 1.44% | 1.04% | 2.37% | 0.71% | 1.82% | -0.88% | 0.54% | -0.03% | 1.08% | -0.26% | 0.38% | 26.23% | 1.82% | 0.42% | 1.40% |
Amphastar Pharmaceuticals's average Quarter net income forecast for Mar 24 is $40.25M, with a range of $38.45M to $43.53M. AMPH's average Quarter net income forecast represents a 11.28% increase compared to the company's last Quarter net income of $36.17M (Dec 23).
Amphastar Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $21.74M | - | $19.00M | $20.59M | $16.10M | $16.77M | $15.73M | $17.99M | $14.70M | $15.65M | $18.69M | $19.88M | $15.82M | $15.35M | $19.95M | $14.04M | $13.98M | $14.24M | $15.42M | $19.47M | $12.72M | $12.82M |
| Avg Forecast | $35.06M | $34.46M | $31.68M | $30.30M | $31.40M | $31.08M | $27.27M | $27.86M | $27.67M | $27.86M | $21.90M | $21.90M | $20.29M | $11.16M | $18.84M | $12.49M | $17.81M | $16.47M | $16.16M | $10.93M | $14.19M | $14.55M | $13.84M | $12.95M | $13.05M | $12.53M | $12.37M | $10.71M | $30.05M | $9.15M |
| High Forecast | $37.26M | $36.62M | $33.67M | $32.20M | $33.37M | $32.84M | $28.98M | $29.61M | $29.04M | $29.61M | $23.27M | $23.27M | $21.56M | $13.39M | $19.96M | $14.99M | $18.87M | $17.46M | $17.13M | $13.12M | $15.04M | $15.42M | $14.66M | $15.54M | $13.83M | $13.28M | $13.11M | $12.85M | $36.06M | $10.99M |
| Low Forecast | $33.86M | $33.28M | $30.59M | $29.26M | $30.32M | $29.86M | $26.34M | $26.91M | $26.29M | $26.90M | $21.15M | $21.15M | $19.59M | $8.93M | $18.15M | $9.99M | $17.15M | $15.87M | $15.57M | $8.74M | $13.67M | $14.02M | $13.33M | $10.36M | $12.57M | $12.07M | $11.92M | $8.57M | $24.04M | $7.32M |
| Surprise % | - | - | - | - | - | - | - | - | 0.79% | - | 0.87% | 0.94% | 0.79% | 1.50% | 0.84% | 1.44% | 0.83% | 0.95% | 1.16% | 1.82% | 1.11% | 1.05% | 1.44% | 1.08% | 1.07% | 1.14% | 1.25% | 1.82% | 0.42% | 1.40% |
Amphastar Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $27.86M, based on 1 Wall Street analysts, with a range of $26.91M to $29.61M. The forecast indicates a 28.15% rise compared to AMPH last annual SG&A of $21.74M (Dec 23).
Amphastar Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| EPS | - | - | - | - | - | - | - | - | $0.68 | - | $0.54 | $0.54 | $0.70 | $0.32 | $0.35 | $0.50 | $0.42 | $0.62 | $0.16 | $0.11 | $-0.13 | $0.08 | - | $0.09 | $-0.02 | $0.03 | $1.01 | $0.02 | $-0.16 | $0.02 |
| Avg Forecast | $1.27 | $1.20 | $1.07 | $1.01 | $0.99 | $1.01 | $0.77 | $0.77 | $0.91 | $0.69 | $0.56 | $0.53 | $0.40 | $0.39 | $0.35 | $0.36 | $0.37 | $0.24 | $0.21 | $0.18 | $0.14 | $0.14 | $0.14 | $0.09 | $0.07 | $0.07 | $0.04 | $0.04 | $0.19 | $0.05 |
| High Forecast | $1.37 | $1.30 | $1.15 | $1.09 | $1.07 | $1.12 | $0.84 | $0.84 | $1.01 | $0.75 | $0.61 | $0.58 | $0.43 | $0.43 | $0.38 | $0.39 | $0.40 | $0.26 | $0.23 | $0.20 | $0.15 | $0.15 | $0.15 | $0.09 | $0.08 | $0.07 | $0.04 | $0.04 | $0.23 | $0.06 |
| Low Forecast | $1.21 | $1.15 | $1.02 | $0.96 | $0.94 | $0.89 | $0.74 | $0.74 | $0.78 | $0.66 | $0.53 | $0.51 | $0.38 | $0.38 | $0.33 | $0.34 | $0.35 | $0.23 | $0.20 | $0.18 | $0.13 | $0.13 | $0.13 | $0.08 | $0.07 | $0.06 | $0.03 | $0.04 | $0.15 | $0.04 |
| Surprise % | - | - | - | - | - | - | - | - | 0.75% | - | 0.96% | 1.02% | 1.75% | 0.81% | 1.01% | 1.39% | 1.14% | 2.58% | 0.76% | 0.60% | -0.95% | 0.57% | - | 1.05% | -0.27% | 0.45% | 28.86% | 0.50% | -0.84% | 0.40% |
According to 1 Wall Street analysts, Amphastar Pharmaceuticals's projected average Quarter EPS for Mar 24 is $0.77, with a low estimate of $0.74 and a high estimate of $0.84. This represents a 13.72% increase compared to AMPH previous annual EPS of $0.68 (Dec 23).
Amphastar Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| IRWD | Ironwood Pharmaceuticals | $4.57 | $11.67 | 155.36% | Buy |
| EVO | Evotec SE | $3.54 | $8.00 | 125.99% | Buy |
| AMPH | Amphastar Pharmaceuticals | $48.09 | $66.00 | 37.24% | Buy |
| EOLS | Evolus | $17.49 | $22.50 | 28.64% | Buy |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| SUPN | Supernus Pharmaceuticals | $31.11 | $38.00 | 22.15% | Buy |
| NBIX | Neurocrine Biosciences | $122.25 | $146.60 | 19.92% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| PBH | Prestige Consumer Healthcare | $74.12 | $82.00 | 10.63% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $21.99 | $18.67 | -15.10% | Buy |
AMPH Forecast FAQ
Is Amphastar Pharmaceuticals a good buy?
Yes, according to 1 Wall Street analysts, Amphastar Pharmaceuticals (AMPH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of AMPH's total ratings.
What is AMPH's price target?
Amphastar Pharmaceuticals (AMPH) average price target is $66 with a range of $66 to $66, implying a 37.24% from its last price of $48.09. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Amphastar Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for AMPH stock, the company can go up by 37.24% (from the last price of $48.09 to the average price target of $66), up by 37.24% based on the highest stock price target, and up by 37.24% based on the lowest stock price target.
Can Amphastar Pharmaceuticals stock reach $70?
AMPH's average twelve months analyst stock price target of $66 does not support the claim that Amphastar Pharmaceuticals can reach $70 in the near future.
What are Amphastar Pharmaceuticals's analysts' financial forecasts?
Amphastar Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $737.24M (high $782.3M, low $711M), average EBITDA is $115.15M (high $122.19M, low $111.06M), average net income is $184.28M (high $200.62M, low $172.28M), average SG&A $117.61M (high $124.8M, low $113.43M), and average EPS is $3.54 (high $3.85, low $3.31). AMPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $824.3M (high $875.97M, low $795.99M), average EBITDA is $128.75M (high $136.82M, low $124.33M), average net income is $236.34M (high $255.6M, low $225.79M), average SG&A $131.5M (high $139.75M, low $126.99M), and average EPS is $4.54 (high $4.91, low $4.34).
Did the AMPH's actual financial results beat the analysts' financial forecasts?
Based on Amphastar Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $593.24M, which missed the average analysts forecast of $622.59M by -4.71%. Apple's EBITDA was $196.99M, beating the average prediction of $97.25M by 102.57%. The company's net income was $137.54M, missing the average estimation of $140.32M by -1.98%. Apple's SG&A was $80.39M, missing the average forecast of $99.32M by -19.06%. Lastly, the company's EPS was $2.6, missing the average prediction of $2.7 by -3.57%. In terms of the last quarterly report (Dec 2023), Amphastar Pharmaceuticals's revenue was $155.65M, missing the average analysts' forecast of $173.43M by -10.25%. The company's EBITDA was $53.98M, beating the average prediction of $27.09M by 99.27%. Amphastar Pharmaceuticals's net income was $36.17M, missing the average estimation of $47.34M by -23.60%. The company's SG&A was $21.74M, missing the average forecast of $27.67M by -21.42%. Lastly, the company's EPS was $0.68, missing the average prediction of $0.91 by -25.24%